
Daily Derm Times: June 9, 2025
Key Takeaways
- Denifanstat shows promising phase 3 results for acne, indicating potential advancements in acne treatment.
- Barzolvolimab, an anti-KIT antibody, rapidly reduces symptoms in antihistamine-refractory chronic spontaneous urticaria.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our
The Rx Recap: June 1-7
This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.
The Weekly Roundup: June 2-6
In case you missed it, this week we had news about denifanstat's promising phase 3 results for acne, emerging therapies in lichen planus, initial insights from RAD 2025, and more.
Dermatology Times' Weekly Crossword: June 9, 2025
Test your knowledge of key words and terms associated with dermatology news from the previous week.
Top 5 Articles of the Week: June 1-6
Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.
Barzolvolimab Demonstrates Rapid Symptom Reduction in Chronic Spontaneous Urticaria
The monoclonal anti-KIT antibody exhibited promise in adults with moderate to severe antihistamine–refractory CSU.
Almirall Is First to Apply WHO-5 Well-Being Index in Dermatological Clinical Trial Endpoints
Almirall is pioneering a holistic approach in dermatology, emphasizing psychological well-being through the WHO-5 index in clinical trials.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















